KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Payables: 2015-2025

Historic Payables for BeOne Medicines (ONC) over the last 10 years, with Sep 2025 value amounting to $1.2 billion.

  • BeOne Medicines' Payables rose 289.22% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 billion, marking a year-over-year increase of 142.24%. This contributed to the annual value of $1.3 billion for FY2024, which is 298.76% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Payables is $1.2 billion, which was up 231.77% from $360.8 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Payables ranged from a high of $1.3 billion in Q4 2024 and a low of $146.9 million during Q1 2021.
  • Its 3-year average for Payables is $485.6 million, with a median of $341.9 million in 2023.
  • As far as peak fluctuations go, BeOne Medicines' Payables crashed by 53.72% in 2021, and later surged by 298.76% in 2024.
  • Over the past 5 years, BeOne Medicines' Payables (Quarterly) stood at $262.4 million in 2021, then increased by 12.34% to $294.8 million in 2022, then rose by 6.90% to $315.1 million in 2023, then surged by 298.76% to $1.3 billion in 2024, then spiked by 289.22% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $360.8 million for Q2 2025, and $364.5 million during Q1 2025.